Abstract
Background. Nuclear factor-κB (NF-κB), a transcription factor known to modulate expression of factors involved in inflammation, immunity, proliferation, and apoptosis, is constitutively activated and plays a role in pathogenesis and therapeutic resistance in head and neck squamous cell carcinoma (HNSCC). Understanding the molecular alterations leading to aberrant NF-κB activation in HNSCC may direct investigators to novel therapeutic targets. Methods. Results of laboratory and clinical studies are reviewed. Results. The structure, function, and activation of NF-κB, products of NF-κB target genes and their role in HNSCC oncogenesis, and current NF-κB modulating interventions are described. Conclusions. Aberrant NF-κB activation contributes to the expression of oncogenes and the malignant phenotype observed in HNSCC. NF-κB, along with providing a link between cancer and inflammation, may serve as an appropriate therapeutic target to inhibit tumor growth and sensitize cancer cells to established cytotoxic anticancer therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 959-971 |
Number of pages | 13 |
Journal | Head and Neck |
Volume | 29 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2007 |
Externally published | Yes |
Keywords
- Bortezomib
- EGFR
- Head and neck squamous cell carcinoma
- Nuclear factor-κB
- Signal transduction
ASJC Scopus subject areas
- Otorhinolaryngology